Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION EFPIA Japan to Compile Policy Proposal on Pricing Reform by Early April: New Chair
March 1, 2017
-
INTERVIEW Daiichi Sankyo Espha Eyes 50 Billion Yen Sales in 2020 with AGs as Growth Engine
February 28, 2017
-
BUSINESS Daiichi Sankyo Takes Aim at Top Spot in Japan Ethical Drug Market: Next President
February 27, 2017
-
INTERVIEW Takeda’s Japan Biz “Going in Good Direction” towards 1st Underlying Sales Rise in 5 Years: Iwasaki
February 24, 2017
-
REGULATORY Overhaul Rules to Pick Comparator Meds in Similar Drug Pricing Method: Chuikyo Rep
February 23, 2017
-
REGULATORY CEFP Working Group to Go Full Throttle on Policy Guidelines Debate in March
February 22, 2017
-
REGULATORY New Formats for Package Inserts to Be Announced in April, Enforced from FY2019 with Transition Period: MHLW
February 21, 2017
-
ACADEMIA AMED Drafts Japan’s First Manual for Treatment of Mitochondrial Diseases
February 20, 2017
-
REGULATORY MHLW Advisory Panel to Review Shionogi’s ADHD Drug on March 2
February 17, 2017
-
TRENDS Daiichi Sankyo Espha Goes on AG Spree as It Wins Nod for 7 Major Brands
February 16, 2017
-
REGULATORY With Eye to June Listing, 24 Generic Makers Flock to Micardis Family, 15 to Abilify
February 16, 2017
-
BUSINESS Takeda, PRA to Launch JV in Japan to Take Over 140 Employees
February 16, 2017
-
BUSINESS Bristol-Myers Looks to Crack into Genotype 1 Hep C Market as Ximency Clears Resistance Mutation Hurdle
February 15, 2017
-
REGULATORY MHLW Mulls Administrative Penalties, Tighter Regulations after Counterfeit Harvoni Case
February 14, 2017
-
REGULATORY Japan’s First Guidance for Development of Cancer Immunotherapies Will Promote Development
February 13, 2017
-
BUSINESS Bayer Yakuhin Ramping Up Digital Transformation: New President
February 10, 2017
-
BUSINESS Harvoni No. 1 Drug in Japan in 2016 with Sales of 296 Billion Yen, More than Any Other Drug Over Past 10 Years: IMS Japan
February 10, 2017
-
REGULATORY Bill Payers, Doctors in Skirmish over Drug Price Survey for Gap-Year Revisions: Chuikyo
February 9, 2017
-
REGULATORY Chuikyo OKs Optimal Use Guidelines for Opdivo and Keytruda, Due Out Feb. 14
February 9, 2017
-
REGULATORY Keytruda Gets Same Daily Price as Opdivo; Chuikyo OKs Batch of Drugs for Feb. 15 Listing
February 8, 2017
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…